New medicines can’t help if patients can’t access them!

New medicines can’t help if patients can’t access them!

Access to medicines in Ireland

  • The rate of availability for new medicines in Ireland is alarmingly low and on par with Bulgaria. Only 43% of medicines approved by the European Medicines Agency (EMA) in 2016 are available in Ireland. This compares with 87% in Austria, Denmark and the UK.
  • Just 20% of new cancer medicines authorised by the European Medicines Agency (EMA) in 2014 and 2015 were available to Irish patients by 2016. This compares to 76% availability in Germany and Austria.
  • There are currently XX cancer medicines waiting to be made available through the public system in Ireland.
  • The time between approval and reimbursement in Ireland has risen dramatically over the past ten years. Irish patients used to be able to access medicines within 3 months of EMA approval. Now it takes an average of 348 days.

The need for a new market access system

  • The Irish market access system is not fit for purpose. Its out-dated model means that it is not capable of assessing the true value of medicines beyond the traditional cost-effectiveness model and endpoints based on overall survival.
  • The Irish system is struggling to cope with the level of applications for new medicines, with 30 medicines already stuck in the system. However, more and more medicines are being developed in labs around the world in many disease areas which will bring further strain to the system.

Need a term explained? Check out the glossary.